Dr. Y K Hamied, Non-Executive Chairman, presided over the meeting, which was attended by several directors including Mr. Abhijit Joshi, Mr. Adil Zainulbhai, Dr. Balram Bhargava, Mr. Kamil Hamied, Dr. Mandar Vaidya, Ms. Maya Hari, Mr. P R Ramesh, Mr. Robert Stewart, Ms. Sharmila Paranjpe, and Mr. Umang Vohra. Also in attendance were key management personnel such as Mr. Ashish Adukia (Global Chief Financial Officer) and Mr. Rajendra Chopra (Company Secretary), along with representatives from the statutory auditor, secretarial auditor, cost auditor, and assurance provider.
During the meeting, shareholders considered and adopted the audited standalone and consolidated financial statements for the fiscal year ended March 31, 2025. They also ratified the remuneration of the cost auditor for the financial year ending March 31, 2026, and appointed secretarial auditors for the Company.
Mr. Umang Vohra, Managing Director and Global Chief Executive Officer, presented a summary of the company's performance in FY25, highlighting robust growth across geographies. Cipla reported revenue of ₹27,548 crore, an 8% year-on-year increase, with an EBITDA of ₹7,128 crore, up by 14%. The company's PAT stood at ₹5,273 crore, reflecting a 28% increase year-on-year. The EBITDA margin was 25.9%, and the PAT margin was 19.1%.
Cipla's One India business reported revenue of ₹11,615 crore, a 7% increase year-on-year. North America contributed $934 million, growing at 3% year-on-year, while One Africa saw a 12% increase with $452 million in revenue. Emerging Markets and Europe reported $390 million in revenue, a 15% increase year-on-year.
The company highlighted key achievements, including Foracort surpassing ₹900 crore in revenue and receiving drug approval for Nilotinib and Nano Paclitaxel in South Africa. Cipla also emphasized its commitment to quality, with all five manufacturing facilities audited by the USFDA in FY25 classified as 'VAI'.
Cipla's commitment to environmental sustainability was also a key focus, with the company achieving 1.75 times water positivity and a 58% reduction in absolute scope 1 and scope 2 GHG emissions compared to FY2019-20. Additionally, 64% of electricity consumed was from renewable sources.
The Cipla Foundation touched the lives of over 338,000 individuals through its work in health, environmental sustainability, education, and disaster response. The company also received several accolades, including the CS National Awards for Excellence in Corporate Governance and certification as a Great Place to Work for the 7th year in a row.
